Incyte said its JAK1 inhibitor povorcitinib delivered success in two Phase 3 trials in nonsegmental vitiligo, and the company plans to file for approval. The readouts position the oral therapy as a potential competitive option in the crowded vitiligo market. The reported Phase 3 wins add to a growing set of late-stage JAK-inhibitor data that will be evaluated for breadth of response and durability, as well as tolerability in long-term use. Analysts will likely compare clinical results directly with existing IL-therapy and JAK competition, including efficacy depth and speed. Separately, Incyte’s results were framed by market commentary as not fully displacing AbbVie’s Rinvoq, setting up continued scrutiny around response rates and the durability curve as regulatory timelines approach.